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Cisplatin is one of the effective chemotherapeutics in the treatment of several types of can-
cers. However, in addition to the efforts against to its toxicity, the amelioration of cisplatin
sensitivity is an important point in treatment of cervical cancer. To do so, additional sub-
stances such as epigallocatechin gallate (EGCG), a polyphenol in green tea, have been used
in combination with chemotherapeutics. We aimed to investigate the possible molecular
pathways to potentiate cervical cancer cell (HeLa) growth inhibition by combination therapy
of cisplatin and EGCG. HeLa cells were treated with EGCG (25µM), cisplatin (250 nM), and
their combination for 24 h. Cell viability was determined by MTS Assay. We analyzed the
expressions of NF-κB p65, COX-2, Nrf2, HO-1, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt
byWestern blot analysis. Herein, we have demonstrated that EGCG works synergistic with
cisplatin in inhibiting growth of cervical cancer cells. EGCG improved efficacy of cisplatin
treatment in HeLa cells by regulating NFκB p65, COX-2, p-Akt, and p-mTOR pathways,
whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. Our obser-
vations revealed that EGCG increases the sensitization of cisplatin to cervical cancer cells
by inhibiting cell survival and inducing apoptosis.
Keywords: cisplatin, epigallocatechin gallate, HeLa cells, human cervical cancer, sensitization
INTRODUCTION
Chemotherapeutic agents, anti-neoplastic cytotoxic drugs, can
greatly improve an individual’s chances of survival by impair-
ing mitosis of fast-dividing cancer cells. Cisplatin (cis-
diamminedichloroplatinum II, CDDP), an inorganic platinum
compound, is one of the effective chemotherapeutic agents in the
treatment of several types of cancer, including cervical carcinomas
(1). As other anti-cancer drugs, the mechanism of cisplatin action
occurs by induction of cell death through DNA damage. However,
it has adverse side-effects such as nephrotoxicity, gastrointestinal
toxicity, neurotoxicity, bone marrow toxicity, and ototoxicity (2).
The common side-effects of cisplatin usage are generally induced
by oxidative stress due to strong electrophilic nature of activated
cisplatin (3). Therefore, the usage of antioxidants in combina-
tion with anti-cancer drugs is increasing for treatment in addition
to their usage in prophylaxis of several diseases including can-
cer. A variety of polyphenolic compounds in plants are known as
chemo-preventive antioxidant agents (4). Nowadays, epigallocate-
chin gallate (EGCG), a major component of polyphenols in green
tea, becomes popular as an icon of antioxidants.
The polyphenolic catechin, EGCG, is believed to be the most
protective agent in the green tea (5). EGCG has a potential to mod-
ify oxidative environments for tumor cell destruction and normal
cell survival (6). In previous studies, EGCG were reported as a
beneficial therapeutic agent for various types of cancers including
lung, ovarian, breast, cervical, and prostate cancers (7–10) due to
inhibiting cell proliferation, angiogenesis, and inducing apoptosis
to prevent the growth of solid tumors (5). EGCG may also pre-
vent the secondary malignancy and weight loss caused by cisplatin
and/or tumors (11). The action of EGCG is believed to occur by
its antioxidative properties. This catechin scavenges free radicals
and prevents mutation and DNA damage by inducing expression
of some enzymes such as glutathione peroxidase, glutamate cys-
teine ligase, and hemeoxygenase-1 (HO-1), which are all involved
in the elimination of reactive oxygen species (ROS) (12). Fur-
thermore, several studies showed that EGCG can also increase the
sensitization of cancer cells to cisplatin even if they are resistant
(13). EGCG is known to block many targets in signal transduction
pathways (12). For example, EGCG tends a potent inhibitor of
Akt/NF-κB and mTOR signaling pathways affecting apoptosis and
cell survival mechanisms (14). Also, this catechin causes nuclear
factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant
induction and reduced inflammation (15). Nrf2, a redox-sensitive
transcription factor, regulates transcriptional activation through
the antioxidant response element (ARE) to prevent the oxidative
stress. The activation of Nrf2 is considered an important molecular
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target of cytoprotective agents. Upregulation of Nrf2 by its acti-
vators resulted in an increased expression of antioxidant enzyme
HO-1 (12). The action of Nrf2 on the prevention of inflamma-
tion enhanced by ROS occurs through the inactivation of nuclear
factor-κB (NFκB) (16).
In one of our studies, we observed that EGCG supplementa-
tion improved the cisplatin-induced nephrotoxicity by reducing
inflammation through NF-κB inactivation. Furthermore, in this
study, we noted that Nrf2/HO-1 signaling pathway may be the pri-
mary target of EGCG for prevention of cisplatin-induced nephro-
toxicity in a mouse model (15). Although there are several studies
related with anti-proliferative and antioxidant activity of EGCG,
there is limited number of published data on in vitro studies of
molecular signaling mechanisms of EGCG on cervical cancer cell
investigating only apoptotic pathways (17). Clearly, much more
research is needed to determine which molecular mechanisms are
responsible for the sensitization of the cancer cells by EGCG to
chemotherapeutic drugs. Therefore, the goal of the current study
is to investigate the possible molecular pathways to potentiate cer-
vical cancer growth inhibition by combination therapy of cisplatin
and EGCG in vitro. In this study, we evaluated the effects of EGCG
and cisplatin on cell growth, apoptosis-related protein expression
and oxidative stress in HeLa, and human cervical cancer cell line.
MATERIALS AND METHODS
CELL CULTURE AND REAGENTS
HeLa cells, the human cervical cancer cell line, were obtained from
American Type Culture Collection (Manassas, VA, USA). They
were maintained in RPMI-1640 medium containing 10% heat
inactivated fetal bovine serum, 1% L-glutamine, 100 U/mL peni-
cillin G, and 100µg/mL streptomycin. Incubations of cells were
done in a humidified, 5% CO2 atmosphere at 37°C. No growth
factors were added to the cell culture medium. EGCG (Teavigo®,
DSM, Istanbul, Turkey) was dissolved in 0.9% saline. Cisplatin
(Sigma Chemical Company, St. Louis, MO, USA) was dissolved in
phosphate buffered saline to make a 0.5 mM stock solution.
CELL VIABILITY ASSAY
Cell viability was determined by MTS Assays. HeLa cells were
seeded 3000 cells in a 96-well plate and incubated overnight.
Cells (2–5× 104) were treated with EGCG (25µM), cisplatin
(250 nM), and their combination treatment for 24 h. After 24 h
of total treatment, the cells were incubated at 37°C with 1 mg/mL
MTS reagent (Sigma, St. Louis, MO, USA) for 2 h. The for-
mazan crystals were dissolved in isopropanol. Spectrophotometric
absorbance of the samples was determined by the ULTRA Multi-
functional Microplate Reader (ELx800-BIO-TEK) at 490 nm. MTS
assay repeated at least three times.
WESTERN BLOT ANALYSIS
The total protein extraction was performed from HeLa cells only,
HeLa cells treated with EGCG (25µM), cisplatin (250 nM), and
EGCG co-treated with cisplatin for 24 h. Sample proteins were sep-
arated by sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE)
and subsequently transferred to a nitrocellulose membrane. Then,
blots on the membrane were incubated with blocking solution
(5% non-fat dry milk). Primary antibody was diluted (1:1000) in
the same buffer containing 0.05% Tween-20. Afterwards, the blots
were incubated overnight with primary antibody, anti-NF-κB p65,
anti-COX-2, anti-HO-1, anti-p-mTOR, anti-p-p70S6K1, antip4E-
BP1, anti-p-Akt (Abcam, Cambridge, UK), and anti-Nrf2 (Santa
Cruz, CA, USA) at 40°C and on the following day, with secondary
antibody (HRP-linked goat anti-mouse IgG, Abcam, Cambridge,
UK) for 1 h at room temperature. Blots were then incubated with
diaminobenzidine and H2O2 as substrates for visualization of
specific binding. Protein loading was controlled using a mono-
clonal mouse antibody against β-actin (A5316; Sigma). Blotting
was performed at least three times to confirm data reproducibility.
Immunoreactive protein bands were quantified densitometrically
using ImageJ analysis system (NIH, Bethesda, USA). Results were
normalized to the β-actin expression in each group as percent of
control. Blots were performed three times.
STATISTICAL ANALYSIS
Group means± SEM were calculated from all measures, which
were repeated at least three times. Data were analyzed by one-way
ANOVA using the GLM Procedure (SPSS version 13.0, Chicago, IL,
USA). The Tukey’s post hoc test option was employed to elucidate
group mean differences. The criterion of statistical significance
was p≤ 0.05.
RESULTS
EGCG ENHANCES THE INHIBITORY EFFECT OF CISPLATIN ON THE
PROLIFERATION OF HeLa CELLS
MTS cell proliferation assay was used to evaluate the effects of
EGCG, cisplatin, and their combination on the proliferation of
HeLa cells. The relative cell viability for each treatment group was
determined according to density of insoluble purple formazan dye
products, which were formed due to reducing MTS by metabol-
ically active cells (18). The individual treatment of cisplatin and
EGCG decreased the growth of human cervical cancer cell lines to
74.7 and 65.5%, respectively. In the combination therapy, EGCG
enhanced the inhibitory activity of cisplatin by decreasing the cell
viability to 37.9% as compared to control group (Figure 1).
EGCG ENHANCES CISPLATIN-INDUCED APOPTOSIS IN HeLa CELLS
Compared to control, cisplatin-only treated cells significantly
increased the expression level of NF-κB p65B, whereas EGCG-only
FIGURE 1 | Growth inhibition of human cervical cancer cell lines
treated with EGCG (25µM), cisplatin (250nM), and the combination
treatments. *Indicates significant difference against to control, # indicates
significant difference against to EGCG, & indicates significant difference
against to cisplatin (p<0.05). Error bars denote SEM.
Frontiers in Nutrition | Clinical Nutrition January 2015 | Volume 1 | Article 28 | 2
Kilic et al. EGCG and cisplatin in HeLa
treated cells significantly decreased this protein level. When
EGCG was applied to the cell culture with cisplatin, expression
level of NF-κB p65B protein significantly reduced compared to
cisplatin-only treated cells group (Figure 2A).
Western blot analysis showed that the expression of cyclo-
oxygenase-2 (COX-2) was significantly higher in the cisplatin-
treated HeLa cells than that of the control cells. The COX-2
expression was significantly decreased by EGCG-only treated cells
FIGURE 2 |Western blot analyses of NF-κB p65, COX-2, Nrf2, and HO-1
in HeLa cells. The intensity of the bands for expression of (A) NF-kB,
(B) COX-2, (C) Nrf2, and (D) HO-1 in HeLa cells were quantified by the
densitometric analysis. Cells untreated or treated with 25µM EGCG,
250 nM cisplatin (Cis), and the combination (EGCG+ cisplatin). β-Actin
antibodies were used as internal controls for equal loading of proteins. Data
are percent of the control. *Indicates significant difference against to
control, # indicates significant difference against to EGCG, & indicates
significant difference against to cisplatin (p<0.05). Error bars denote SEM.
and co-treated cells with cisplatin as compared with cisplatin-only
treated cells (Figure 2B).
EGCG REDUCES CISPLATIN-INDUCED OXIDATIVE STRESS IN HeLa
CELLS
To observe the role of EGCG in oxidative stress mechanisms, the
expression of Nrf2 and HO-1 were evaluated by Western Blot
analysis. The expression levels of Nrf2 and HO-1 significantly
decreased in the cisplatin-only treated HeLa cells compared with
those expressions in the control HeLa cells (Figures 2C,D). It was
shown that EGCG increased Nrf2 and HO-1 accumulation in the
nuclear fraction of EGCG-only treated cells compared to control
cells. Combined treatment of cisplatin and EGCG was signifi-
cantly increased these protein levels as compared to cisplatin-only
treated cells.
EGCG INHIBITS CISPLATIN-INDUCED ACTIVATION OF mTOR PATHWAY
IN HeLa CELLS
In order to evaluate the involvement of mTOR molecular path-
way in the anti-proliferative effect of cisplatin and ECGC in HeLa
cells, we assessed the expression levels of p-mTOR, p-p70S6K1,
p-4E-BP1, and p-Akt. Individual treatment of ECGC significantly
reduced the level of phosphorylated mTOR, p70S6K1, 4E-BP1,
and Akt in cervical cancer cells, while individual cisplatin treat-
ment significantly increased their levels compared to control
(Figures 3A–D). The combined therapy of EGCG and cisplatin
attenuated the cisplatin-induced effects by decreasing the lev-
els of p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt compared to
cisplatin-only treated cells.
DISCUSSION
Cisplatin is a major chemotherapeutic agent for the treatment of
cervical carcinomas as used in other cancer types. However, in
addition to the efforts against to its toxicity, the amelioration of
cisplatin sensitivity is an important point in treatment of cervi-
cal cancer. Besides, the usage of chemotherapy alone is generally
ineffective against well-established tumors. Nowadays, additional
substances such as antioxidants in combination with chemother-
apeutic agents have been used to overcome the intrinsic resistance
against therapy for tumors (19). Antioxidants have a dual effect
in carcinomas. In addition to protection against cisplatin-induced
toxicity, they also increase the sensitization of cancer cells to cis-
platin (20, 21). Recently, the green tea polyphenol EGCG has
gained attention as a natural agent for its chemo-preventive and
anti-proliferative properties against various types of carcinomas.
In the current study, we examined the action of EGCG on cisplatin-
treated cervical cancer cells. We found that addition of EGCG to
the cisplatin-treated cervical cancer cells attenuated the toxicity of
cisplatin by decreasing cellular survival and inducing apoptosis.
The effect of EGCG on cisplatin’s chemotherapeutic activity has
been previously reported for ovarian cancer (13), prostate cancer
(22), and head and neck squamous carcinoma (23). In this study,
compared to individual cisplatin treatment, we observed that com-
bination treatment of EGCG and cisplatin significantly enhances
the inhibition of cellular growth of cervical cancer cells in vitro as
suggested in a recent study performed by Singh et al. (17). One
of problem in the cancer chemotherapy is further increase the
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FIGURE 3 |Western blot analyses of p-mTOR, p-p70S6K1, p-4E-BP1,
and p-Akt in HeLa cells. The intensity of the bands for expression of
(A) p-mTOR, (B) p-p70S6K1, (C) p-4E-BP1, and (D) p-Akt in HeLa cells were
quantified by the densitometric analysis. Cells untreated or treated with
25µM EGCG, 250 nM cisplatin (Cis), and the combination
(EGCG+ cisplatin). β-Actin antibodies were used as internal controls for
equal loading of proteins. Data are percent of the control. *Indicates
significant difference against to control, # indicates significant difference
against to EGCG, & indicates significant difference against to cisplatin
(p<0.05). Error bars denote SEM.
concentration of chemotherapeutic agent, thereby, increase in the
cellular toxicity. Therefore, the sensitization of cisplatin-induced
growth inhibition of HeLa cells by EGCG may be a remedy for
chemotherapeutic drug toxicity-induced damages. The potentia-
tion of cancer cell growth inhibition by EGCG was directed us to
find the possible target pathways for how EGCG sensitize the HeLa
cells to cisplatin.
Activation of mTOR signaling pathway is associated with cell
survival in cervical cancer cells (21). mTOR is known to regu-
late initiation of translation through two pathways: S6K and 4E-
BP1 (24). Herein, we have found increased p-mTOR, p-p70S6K1,
and p-4E-BP1 expressions after cisplatin treatment, which down-
regulated by the addition of EGCG. These results suggest that
the prevention of mTOR pathway upregulation occurs through
p70S6K1 and 4E-BP1 proteins. Parallel changes were observed in
the expression level of phosphorylated Akt suggesting presence
of a crosstalk between mTOR pathway and Akt pathway in the
sensitization mechanism of EGCG. The activation of Akt has a
role in the development of chemotherapeutic drug resistance and
reduction of the apoptotic-potential of chemotherapeutic agents
in several cancer types (17). Therefore, the inhibitor agents of the
Akt pathway can improve cisplatin-induced chemotherapy (17).
EGCG is also reported as a potent inhibitor of Akt signaling path-
way (14). Thus, inducing apoptosis by regulating Akt pathway may
be a mechanism for inhibition the growth of cervical cancer cells.
Cisplatin-induced oxidative stress was previously reported in
different tissues (20, 25). It has been shown that cisplatin trig-
gers its toxicity by enhancing ROS production and TNF-α level,
reducing the levels of antioxidant enzymes,and inducing apoptosis
(25). One of the molecular target of cisplatin-induced oxida-
tive stress is Nrf2/HO-1 pathway (12, 20). Nrf2 protects the cell
against oxidative stress by inducing of several phase 2 detoxify-
ing and antioxidant enzymes, such as HO-1. In this study, we
observed that expression levels of Nrf2 and HO-1 reduced sig-
nificantly in the cisplatin-only treated cells compared to control
HeLa cells demonstrating the cisplatin cytotoxic activity on cancer
cells through increasing oxidative stress. However, the combined
therapy of cisplatin and EGCG increased Nrf2 and HO-1 expres-
sions in the cervical cancer cells compared to cisplatin-only treated
cells. This result suggested that EGCG activates Nrf2 pathway
due to the effect of electrophiles induced by cisplatin. Previous
studies demonstrated that overexpression of Nrf2/HO-1 confers
resistance to apoptosis induction by EGCG (26). Under physiolog-
ical conditions, cytosolic Nrf2 is inactive by its negative regulator
Kelch-like ECH-associating protein 1 (Keap1). The EGCG’s action
on Nrf2 pathway might be due to its interaction with Keap1 thi-
ols. When cells are exposed to redox modulators, in this case
EGCG treatment, Nrf2 is released from Keap1 protein and hence
translocates and accumulates in the nucleus acting as an elec-
trophiles and pro-oxidant stressors sensor (27). The activation of
Nrf2 may transcriptionally regulate an antioxidative gene, HO-1
(12). These results suggest that EGCG may stimulate the synthesis
of antioxidant systems using Nrf2 pathway. The EGCG’s cyto-
protective mechanism by activating Nrf2-mediated antioxidant
response is best demonstrated in animal studies (12, 15, 27). How-
ever, in cancer cells, the overexpression of Nrf2/HO-1 by EGCG
promotes the survival of cancer cells under a deleterious environ-
ment such as cisplatin-induced oxidative stress. This condition
decreases Keap1 expression and upregulates the Nrf2 expression
resulting in removal of ROS and protection of cancer cells (28).
The oxidation and nitration of another oxidative stress sensi-
tive molecular target, transcription factor NF-κB, which is induced
by Nrf2-driven transcriptional activation of ARE, has an essen-
tial role in the oxidant/redox signaling (16). Therefore, various
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physiological and pathological stimuli like ROS activate this pro-
tein. NF-κB also plays an important role in apoptosis mechanisms
by exerting its regulatory effects on survival genes in addition to its
role in inflammation (16). Similar to previous observations, in the
current study, cisplatin treatment significantly increased NF-κB
p65 protein level. It was shown that disruption of Nrf2 enhances
the upregulation of NF-κB (26) in agreement with our study.
Also, activated NF-κB has also been identified as a key mecha-
nism of cisplatin resistance (29). Previous studies done in different
cancer cell lines, like epidermoid carcinoma cells and head and
neck squamous cell carcinoma, showed that upregulation of NF-
κB activation can result cisplatin resistance either by influencing
expression of Bcl-2 family members or MAPK signaling pathways
and regulating chromatin remodeling (30, 31). EGCG treatment
downregulated the increase in the expression level of NF-κB p65
induced by cisplatin as compared to individual cisplatin treatment
pointing the potent antioxidative capacity of EGCG. The decrease
of this protein expression in cancer cells by plant extracts is also
supported by our previous studies (21) and other researchers (26).
COX-2, an NF-κB target gene, is expressed at high levels in
pathological circumstances and oncogenesis (32). In carcinogene-
sis, COX-2 is related with abnormal arachidonic acid metabolism
due to its role in biosynthesis of prostaglandins through the con-
version of arachidonic acid. Parallel to NF-κB expression, the
protein expression of COX-2 was higher in cisplatin-only treated
HeLa cells whereas EGCG-only treated cells and co-treated cells
decreased COX-2 level compared to control and cisplatin-only
treated HeLa cells. Given that the COX-2 is associated with (32), it
is proposed that the downregulation of COX-2 by EGCG may have
beneficial effects on reversing the cisplatin-induced apoptosis inhi-
bition, thus, offering protection against cancer development (33).
These results possibly suggested that EGCG’s chemo-preventive
activity may occur through suppression of COX-2 target gene
expression by inhibiting NF-κB to stop proliferation of cancer cells.
Herein, we have demonstrated that EGCG works synergistic
with cisplatin in inhibiting growth of cervical cancer cells. Our
findings suggest that cisplatin treatment is potentiated with EGCG
in HeLa cells by regulating NFκB p65, Akt, and mTOR pathways,
which are critical for cell survival and apoptosis. Collectively, our
observations reveal that cisplatin and EGCG combination could be
used to improve the treatment in cervical cancer through decreas-
ing cell survival and enhancing apoptosis. This combination is a
less toxic option in the treatment of cervical cancer, especially if
there is chemoresistance to cisplatin. Therefore, this study may
give a hint at chemotherapeutic uses of EGCG. Future in vivo
and in vitro inhibition studies are warranted to investigate the
combination of cisplatin and EGCG in cervical cancer when con-
sidered the high incidence rate of cervical cancer and associated
side-effects of current treatment modality.
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